The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year



Unattributed | Alive

Total Raised


About SanBio

SanBio is a regenerative medicine company with cell-based products in various stages of research, development, and clinical trials. Its proprietary cell-based product, SB623, was built for treatment of chronic motor impairments resulting from stroke.

SanBio Headquarter Location

St. Luke Tower 28F 8-1 Akashi-cho, Chuo-ku

Tokyo, 104-0044,


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing SanBio

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

SanBio is included in 2 Expert Collections, including Regenerative Medicine.


Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).


Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

SanBio Patents

SanBio has filed 43 patents.

The 3 most popular patent topics include:

  • Stem cells
  • Clusters of differentiation
  • Transcription factors
patents chart

Application Date

Grant Date


Related Topics




Transcription factors, Clusters of differentiation, Angiology, Stem cells, Proteins


Application Date


Grant Date



Related Topics

Transcription factors, Clusters of differentiation, Angiology, Stem cells, Proteins



Latest SanBio News

SanBio’s SB623 demonstrated sustained improvement in motor impairment in brain injury

Apr 8, 2022

31-03-2022 Japan’s SanBio Group (TYO: 4592) has announced that SB623 met the primary endpoint and demonstrated a trend toward maintaining the improvement of function and activities of daily living in the final, one-year analysis of the Phase II STEMTRA trial, which evaluated the efficacy and safety of SB623 compared to sham surgery in patients with chronic motor deficit from traumatic brain injury (TBI). These results will be presented in an oral session… This article is accessible to registered users, to continue reading please register for free . A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please  login . If your trial has come to an end, you can  subscribe here. • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech. • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results. • Daily roundup of key events in pharma and biotech. • Monthly in-depth briefings on Boardroom appointments and M&A news. • Choose from a cost-effective annual package or a flexible monthly subscription. If you are already a registered user please login . The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed Chairman, Sanofi Aventis UK

SanBio Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

SanBio Rank

  • When was SanBio founded?

    SanBio was founded in 2001.

  • Where is SanBio's headquarters?

    SanBio's headquarters is located at St. Luke Tower 28F, Tokyo.

  • What is SanBio's latest funding round?

    SanBio's latest funding round is Unattributed.

  • How much did SanBio raise?

    SanBio raised a total of $20M.

  • Who are the investors of SanBio?

    Investors of SanBio include CareNet, Medical Incubator Japan and California Institute of Regenerative Medicine.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.